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Abstract
Background: The effects of statins in patients with diabetic nephropathy are controversial. With increasing interest
in the potential therapeutic role of statins in diabetic nephropathy, it is essential to evaluate its real effects.
Methods: PubMed, EMBASE, Web of Science databases, Cochrane Central Register of Controlled Trials and China
National Knowledge Infrastructure were systematically searched for randomized controlled trials (RCTs) of statins in
patients with diabetic nephropathy.
Results: Fourteen trials with 2866 participants were included in our meta-analysis. Compared with placebo, albuminuria
and urinary albumin excretion rates in the statin group were reduced by 0.46 [95 % confidence interval (CI),−0.68 to
−0.25, P < 0.0001] and 1.68 (95 % CI, −3.23 to −0.12, P = 0.03), respectively. The reduction of albuminuria was greater
in patients of type 2 diabetes mellitus with diabetic nephropathy [standardized mean difference (SMD), −0.56; 95 % CI,
−0.80 to −0.32, P < 0.00001] and the decrease was significant during the 1 to 3 years period of statin therapy (SMD,
−0.57; 95 % CI, −0.95 to −0.19, P = 0.003). Subgroup analysis demonstrated the effects of statins were much stronger
in subjects with pathologic albuminuria: change of −0.71 (95 % CI, −1.09 to −0.33, P = 0.0003) for those with
urinary protein excretion 30 to 300 mg/day, −0.37 (95 % CI, −0.67 to −0.06, P = 0.02) for those with excretion
more than 300 mg/day and −0.29 (95 % CI, −0.78 to 0.21, P = 0.26) for those with excretion less than 30 mg/day.
In contrast, statins did not significantly reduce estimated glomerular filtration rate, serum creatinine and blood
urea nitrogen levels.
Conclusions: Statins decrease the albuminuria and urinary albumin excretion rates significantly. The efficacy of
statins on renal function is time dependent and better in type 2 diabetic patients with nephropathy.
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Background
According to the International Diabetes Federation [1],
it is projected that the number of people with diabetes
worldwide will increase from 382 million in 2013 to 592
million by 2035. Diabetic nephropathy (DN) is one of
the most common and serious chronic complication of
diabetes and it is the leading cause of end-stage renal
disease [2]. However, beyond angiotensin II-receptor
blockers (ARB) and angiotensin-converting enzyme
inhibitors (ACEI), therapeutic options to block the pro-
gression of diabetic nephropathy are limited and other
strategies to preserve kidney function are needed.
A number of potential mechanisms for kidney damage
in DN have been identified. Hyperlipidemia may play an
important role in the progression of DN and it may
impair the messangial cells through its lipotoxicity or by
promoting intrarenal atherosclerosis [3–5]. Statin, 3-
hydroxy-3 methylglutaryl coenzyme A (HMG CoA)
reductase inhibitor, is a kind of antihyperlipidemic drug
that used worldwide for its strong low-density lipopro-
tein cholesterol (LDL-C)-lowering effects and established
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safety. Recently, there are growing studies suggested that
statins may offer renoprotective effects and beneficial
effect on pathologic albuminuria and decrease the
reduction of estimated glomerular filtration rate (eGFR)
[6–8]. However, some trials [9, 10] failed to demonstrate
that statin improve eGFR.
To assess whether statins have beneficial effects on
renal outcomes in diabetic nephropathy, we performed
this meta-analysis to investigate the potential therapy of
statins in patients with diabetic nephropathy.
Methods
Literature search
We conducted a search of PubMed, EMBASE, Web of
Science databases, Cochrane Central Register of Controlled
Trials and China National Knowledge Infrastructure
(CNKI). All relevant articles were published in English and
Chinese. The following Medical Subject Headings (MeSH)
and text words were used: Hydroxymethylglutaryl-CoA
reductase inhibitors, atorvastatin, simvastatin, rosuvastatin,
pravastatin, lovastatin, fluvastatin, cerivastatin, mevastatin,
pitavastatin, statin, kidney, renal, diabetic nephropathy, ran-
domized controlled trial (RCT), controlled clinical trial and
random allocation. We also searched the additional trials at
the trial register centres (http://www.clinicaltrials.gov).
Clinical trials were included if the following criterias were
met: (1) Primary study of statins versus control (placebo or
usual care); (2) Diabetic nephropathy patients with type 1
and type 2 diabetes mellitus at least 18 years old without
pregnancy; (3) Patients with diabetic nephropathy in experi-
mental group were defined as those who used statins,
regardless of dosages, mode of administration or treatment
duration; (4) RCT design; (5) Report of baseline and the
end of follow-up data on renal function [estimated
glomerular filtration rate (eGFR), urinary albumin excretion
rates (UAER), serum creatinine (Scr), blood urea nitrogen
(BUN) or albuminuria). Exclusion criteria included: (1)
Kidney damage due to diseases other than type 1 or type 2
diabetes. (2) The final stage of diabetic nephropathy or end-
stage-renal disease (ESRD), defined as onset of renal
replacement therapy or death attributed to diabetic
nephropathy.
Study selection and data extraction
Two reviewers independently screened abstracts accord-
ing to the inclusion criteria, and disagreements between
reviewers were resolved by consensus. We developed a
data extraction sheet based on the Cochrane Consumers
and Communication Review Group’s data extraction
template. One reviewer extracted the following data
from included studies and the second reviewer verified
the extracted data. Disagreements were resolved by
discussion between the two reviewers. If an agreement
could not be reached between two reviewers, a third
author would decide. Information extracted included: (1)
characteristics of trial subjects (including age, sex ratio,
duration of diabetes and baseline value of renal function)
and the trial’s inclusion/exclusion criteria; (2) type of
intervention (including dosage, duration and frequency);
and (3) type of outcome and measurement.
Statistical analysis
The primary outcome was the change of albuminuria
from the baseline. Other outcomes include: change from
baseline in eGFR, UAER, Scr, BUN. The meta-analysis
with fixed-model or random-model was performed by
weighted mean difference (WMD), standardized mean
difference (SMD) and 95 % confidence interval (CI) for
outcome of continuous variables. Subgroup analysis by
characteristics of patients (i.e., ethnicity, stage of diabetes
nephropathy) and study design (i.e., whether ACEI/ARB
was used or not) were performed. I2 was calculated as an
index of heterogeneity between studies. If I2 was higher
than 50 %, the sensitive analysis should be performed to
find out the source of heterogeneity and to assess whether
the results could be significantly influenced.
Quality assessment and publication bias
Study quality and bias risk were assessed via predefined
categories: randomization, allocation concealment, quality
of blinding (participants,personnel and outcome assess-
ment), withdrawal and loss and reporting bias. Two
reviewers independently determined these items. Sensitive
analysis was performed in studies with low quality. The
analyses were performed using Review Manager 5.2
(Cochrane Collaboration, http://www.cochrane.org).
Results
Search results and study characteristics
Initially, 929 potentially relevant articles were identified.
After adjusting for duplicates, 603 studies remained, con-
sisting of 134 potentially relevant studies and 469 studies
that were excluded after reviewing titles and abstracts. Of
134 potentially relevant studies, 120 failed to match the
inclusion criteria. Finally 14 articles [9–22] with a total of
2866 participants were included in this meta-analysis
(Fig. 1). Of these, 3 studies [20–22] were reported in
Chinese, 11 were in English [9–19]. Among the final 14
studies, 7 were conducted in Caucasians and others in
Asians. The most commonly diabetic nephropathy included
in this meta-analysis was diabetic nephropathy with type 2
diabetes mellitus. Ten studies provided data of albuminuria,
5 of eGFR, 5 of UAER, 4 of Scr and 2 of BUN. Eight differ-
ent statins involved in this study, including simvastatin [12,
13, 15, 17, 22], atorvastatin [9, 11, 20, 21], pitavastatin [18],
lovastatin [14], cerivastatin [19], rosuvastatin [10] and
pravastatin [16]. The study period ranged from approxi-
mately 3 months to 2 years. ACEI or ARB were used in
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studies, except for 3 studies [11, 15, 17]. The charac-
teristics of the included studies were shown in Tables 1
and 2. Among them, 7 studies [9, 10, 12, 14, 20–22]
mentioned the specific randomized method, the others
referred “random” but did not mention the detail.
Nine studies [9, 11–13, 15–19] were double-blinded.
Detail was shown in Fig. 2.
Quantitative data analysis
Effect of statins on albuminuria
Pooled data from 10 studies [11–17, 19, 21, 22] (20
groups) showed a statistical decrease in albuminuria
compared with that in control group (SMD, −0.46; 95 %
CI, −0.68 to −0.25; P < 0.0001), and the standardized
mean difference in change from baseline was −0.71
(95 % CI, −1.09 to −0.33; P = 0.0003; I2 = 33 %) for those
with excretion of 30 to 299 mg/d; and −0.37 (95 % CI,
−0.67 to −0.06; P = 0.02; I2 = 0 %) for those with excre-
tion of 300 or greater (Fig. 3). Although the statins were
not the same subtype, there was no significant hetero-
geneity among all trials in our study (I2 = 24 %).
Statin did not decrease the urine albumin for those with
excretion less than 30 mg/d (SMD,–0.29; 95 % CI,–0.78 to
0.21; P = 0.26, Fig. 3). In statin treated group, there was
Fig. 1 Flow diagram of study selection
Table 1 Fifteen randomized, placebo-controlled trials assessing the effect of statins on renal outcomes in diabetic nephropathy
Studies Country Intervention Sample
sizes (n)








statin control statin control statin control statin control
CARDS 2009 [9] UK Atorvastatin, 10 mg/d 1154 1159 44.6 43.6 61.5 61.8 — — 24
Masanori 2011 [10] Japan Rosuvastatin, 2.5–10 mg/d 52 52 100 100 64.5 64.9 — — 6
Dalla 2003 [11] Italy Atorvastatin 10 mg/d 12 13 0 0 66 63 10 9 12
Linda 2001 [12] USA Simvastatin, 10 mg/d 19 20 5 15 33.3 31.0 22.8 20.8 18
E. Hommel 1992 [13] Denmark Simvastatin, 10–20 mg/d 12 9 67 89 41 35 27 27 3
Lam 1995 [14] China Lovastatin, 30 mg/d 16 18 12.5 16.7 58.9 53.9 — — 24
S.Nielsen 1993 [15] Denmark Simvastatin 10–20 mg/d 8 10 0 0 65 65 10.2 10.9 9
Zhang 1995 [16] Belgium Pravastatin, 20 mg 10 10 — — 43 43 — — 3
Giancarlo 1997 [17] Italy Simvastatin, 20 mg/d 10 9 0 0 60 62 — — 12
Tsukasa 2005 [18] Japan Pitavastatin, 1 mg/d 10 10 — — 51 49 13 12 12
Tsukasa 2001 [19] Japan Cerivastatin, 0.15 mg/d 30 30 — — 58 55 — — 6
Wu 2013 [20] China Atorvastatin, 20 mg/d 39 39 100 100 55.15 55.33 5.18 4.82 6
Du 2015 [21] China Atorvastatin, 20 mg/d 26 26 100 100 56 57 10 10 3
Xiang 2005 [22] China Simvastatin, 20 mg/d 32 31 100 100 50 49 15 14 6
USA the United States of America, UK United Kingdom, T2DM type 2 diabetes mellitus, T1DM type 1 diabetes mellitus, —:not report
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statistically significant reduction in albuminuria in the
T2DM with diabetic nephropathy (SMD,–0.56; 95 % CI,–
0.80 to −0.32; P < 0.00001, I2 = 14 %), while no significant
improvement in diabetic nephropathy of T1DM subgroup
(SMD, −0.11; 95 % CI, −0.52 to 0.50; I2 = 0 %; P = 0.97,
Fig. 4). A greater decrease in albuminuria was observed in
patients received statin therapy for 1 to 3 years (SMD,
−0.57; 95 % CI, −0.95 to −0.19, P = 0.002) compared with
those <1 year (SMD;–0.41, 95 % CI,–0.67 to −0.15, P =
0.003; Table 3). However, there was no significant difference
between Asians (SMD −0.46, 95 % CI −0.80 to −0.12) and
Caucasians population (SMD −0.54, 95 % CI −0.82 to
−0.27; Table 3).
Therefore, the results suggested that statins can reduce
albuminuria significantly in patients of T2DM with diabetic
nephropathy. And the beneficial effect of statins on renal
function are significantly better in those with statin therapy
longer than one year than that of less than one year.
Effect of statins on estimated glomerular filtration rate
(eGFR)
Six studies [9, 10, 13–15, 17] enrolled, including 2509
participants with eGFR >60 ml/min/1.73 m2. Statins did
not improve eGFR significantly in most studies and the
change in the SMD of eGFR was 0.49 (95 % CI, −0.06 to
1.03, P = 0.08, I2 = 0 %). Furthermore, different types of
diabetic nephropathy, ethnicity, baseline of eGFR, treat-
ment duration and dose of statins also did not influence
eGFR in patients with statin and control therapy
(Table 3).
Effect of statins on urinary albumin excretion rates (UAER)
The effect of statins on UAER was favorable in 5 studies
[15, 16, 18, 20, 22]. Overall, the change in the SMD for
UAER was −1.68 (95 % CI, −3.23 to −0.12, P = 0.03;
Fig. 5) which indicated that compared with placebo,
there was statistically significant reduction in UAER in
Table 2 Characteristics of the 14 randomized controlled trials Included in the meta-analysis


















CARDS 2009 [9] — — — — — —
Masanori 2011 [10] 137 −54 49 +4 162 −32
Dalla 2003 [11] 149 −41 55 +1 162 −32
Linda 2001 [12] 125.5 −28.3 50.9 +2.2 76 −9.5
E. Hommel 1992 [13] 162.54 −61.92 57.7 +1.55 120.5 +11.52
Lam 1995 [14] 166.4 −50.31 42.57 −0.39 194.92 −17.72
S.Nielsen 1993 [15] 170.28 −58.05 48.76 −0.39 204.7 −20.4
Zhang 1995 [16] 123 −23 62 +1 105 −12
Giancarlo 1997 [17] 181.89 −54.18 50.31 0 141.8 −26.6
Tsukasa 2005 [18] — — — — — —
Tsukasa 2001 [19] 208 −62 22 +16 202 −42
Wu 2013 [20] 171.05 −61.15 — — 225.9 −65.6
Du 2015 [21] — — — — — —
Xiang 2005 [22] 166.41 −19.35 54.18 +7.74 221.5 −17.72
aIn statin group;—:not report
Fig. 2 Methodological quality of the included studies
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statin-treated group. Because of the heterogeneity
(heterozygosity test, Chi2 = 56.01, P < 0.00001, I2 =
93 %), we conducted a subgroup analysis and sensitiv-
ity analysis. In subgroup analysis of ethnicity, stage of
diabetic nephropathy, treatment duration and dose of
statins, the heterogeneity still existed (Table 3). When
the trials by Nielsen et al. (1993) [15], Zhang et al.
(1995) [16] and Wu et al. (2013) [20] were removed,
the heterogeneity disappeared (the I2 reduced from
93 % to 0 %, P from <0.00001 to 0.76). The fixed-
effect model was used to merge SMD values and the
pooled SMD was −1.16 (95 % CI,–1.63 to −0.69, P <
0.00001), which indicated that statins reduced UAER
significantly in patients with DN.
Effect of statins on serum creatinine (Scr)
We identified 4 randomized controlled trials [19–22]
(253 participants) for the effect of statins on Scr.
Because of the heterogeneity (heterozygosity test, Chi2 =
64.91, P <0.00001, I2 = 95 %), we removed 1 study at a
time to identify the source of heterogeneity. When the
Study by Tsukasa et al. (2001) [19] was removed, the
heterogeneity was no longer existence, which showed
that the heterogeneity may came from the country
difference of patients in the study. The fixed-effect
model was used to merge SMD values and the pooled
SMD was −0.10 (95%CI,–0.38 to 0.19; P = 0.50; Table 3),
which means statins may have no effect on the Scr in
patients with DN.
Effect of statins on blood urea nitrogen (BUN)
The result showed that there was no statistically
difference in BUN in statin group compared with that
in control group (SMD, −0.26; 95 % CI, −0.64 to 0.13;
P = 0.20) and the heterogeneity among trials was not
significant (I2 = 0 %, Table 3).
Assessment of publication bias
Publication biases were examined by funnel plot and no
significant publication bias was found among studies
included in our meta-analysis (Fig. 6).
Subgroup and sensitivity analysis
Because of study heterogeneity, subgroup and meta-
regression analyses were conducted by ethnicity, baseline
of albuminuria, treatment duration, and dose of statins
(Table 3). However, the results of statin on renal function
were not influenced. In consideration of the different
baseline of UAER, sensitivity analysis was performed to
assess the impact of every study on the overall
Fig. 3 Forest plots of albuminuria after statins or placebo therapy in patients with albuminuria <30 mg/day, 30 to 300 mg/day, and >300 mg/day
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conclusions. After the three trials by Nielsen et al. (1993)
[15], Zhang et al. (1995) [16] and Wu et al. (2013) [20]
were eliminated, the heterogeneity test (the I2 reduces
from 93 % to 0 %, P from <0.00001 to 0.76) indicated that
baseline of UAER may be a source of heterogeneity
(Fig. 7).
Discussion
Statins are frequently used to improve lipid profile and
they are also reported to reduce cardiovascular events
[23], albuminuria [6] and diabetic glomerulosclerosis in
experimental animals [24]. However, the efficacy of sta-
tins in improving renal function in patients with diabetic
nephropathy is still controversial. To answer this ques-
tion, we did this study and found that statins could
reduce the albuminuria and UAER compared with that
in control groups. The beneficial effect of statins on
renal function is time dependent and better in type 2
diabeties with nephropathy.
As we all know, the degree of albuminuria is a risk factor
for renal failure [25]. Some studies have demonstrated a
benefit of statins on albuminuria [6, 26, 27], while others
failed to indicate such an effect [16, 28]. Our meta-analysis
suggested an overall significant decrease of albuminuria
after statin therapy (decrease by 0.46, P < 0.0001), with the
greater improvement of albuminuria among studies with
greater baseline albuminuria. Notably, our results are con-
sistent with the meta-analysis performed by Kevin Douglas
et al. [29]. The beneficial effect of statins on albuminuria
may be potentially explained by cholesterol dependent
effects and cholesterol independent effects [30]. Keane et al.
[31] have showed that dyslipidemia contributes to glomeru-
lar and interstitial injury and the severity of the hyperchol-
esterolemia correlates with albuminuria. In addition, statins
may have other cholesterol-independent renoprotective
actions, such as reducing neutrophil and macrophage infil-
tration, up-regulating endothelial nitric oxide (NO)
synthase, inhibition of renal cell proliferation, antifibrotic
and antioxidant effects, and down-regulation of inflamma-
tory cytokines [32]. Researches suggested that statins
reduce albuminuria at least in part by reducing inflamma-
tion and fibrosis in the renal interstitium, seemingly
through actions on monocyte chemotactic protein-1 and
transforming growth factor-β (TGF-β) [33, 34].
A recent review [32] reported that the benefit of sta-
tins may depend on the duration of treatment. We also
investigated the effect of statin treatment less than 1 year
and between 1 and 3 years. A greater decrease of
albuminuria was observed in patients received statin
therapy for 1 to 3 years compared with those for less
Fig. 4 Forest plots of albuminuria after statins or placebo therapy in nephropathy patients with T1DM or T2DM
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Table 3 Meta-analysis of the effect of statins on renal outcomes in diabetes
Subjects Heterogeneity
Category N cases/controls Ph I2(%) SMD(95 % CI) Z test
Albuminuria
1. Overall 10 175/176 0.22 24 −0.46(−0.68,–0.25) z = 4.21,pz < 0.0001
2. Adjustment by ethnicity
Caucasian 6 71/71 0.12 43 −0.41(−0.75,–0.07) z = 2.36,pz = 0.02
Asian 4 104/105 0.41 0 −0.50(−0.77,–0.22) z = 3.51,pz = 0.0004
3. Adjustment by subtypes of diabetes with diabetic nephropathy
T1DM 2 31/29 0.96 0 −0.01(−0.52,0.50) z = 0.04,pz = 0.97
T2DM 8 144/147 0.31 14 −0.56(−0.80,–0.32) z = 4.63,pz < 0.00001
4. Adjustment by baseline of albuminuria
< 30 mg/d 2 31/33 0.14 53 −0.29(−0.78,0.21) z = 1.12,pz = 0.26
30-299 mg/d 4 58/59 0.21 33 −0.71(−1.09,–0.33) z = 3.65,pz = 0.0003
≥ 300 mg/d 4 86/84 0.42 0 −0.37(−0.67,–0.06) z = 2.37,pz = 0.02
5. Adjustment by treatment duration
< 1 year 6 118/116 0.50 0 −0.41(−0.67,–0.15) z = 3.09,pz = 0.002
1 ~ 3 years 4 57/60 0.07 58 −0.57(−0.95,–0.19) z = 2.94,pz = 0.003
6. Adjustment by dose of statins
low-intensity statins 3 61/63 0.18 41 −0.48(−0.84,–0.12) z = 2.61,pz = 0.009
moderate-intensity statins 2 20/19 0.27 16 −0.35(−0.99,0.30) z = 1.05,pz = 0.29
high-intensity statins 5 94/94 0.13 44 −0.47(−0.77,–0.18) z = 3.15,pz = 0.002
eGFR
1. Overall 6 1252/1257 0.73 0 0.49(−0.06,1.03) z = 1.75,pz = 0.08
2. Adjustment by ethnicity
Caucasian 5 1184/1187 0.48 0 0.48(−0.08,1.04) z = 1.69,pz = 0.09
Asian 1 68/70 0.75 0 0.64(−1.87,3.15) z = 0.50,pz = 0.62
3. Adjustment by subtypes of diabetes with diabetic nephropathy
T1DM 1 12/9 not applicable −3.00(−17.22,11.22) z = 0.41,pz = 0.68
T2DM 5 1240/1248 0.64 0 0.49(−0.05,1.04) z = 1.77,pz = 0.08
4. Adjustment by baseline of albuminuria
< 30 mg/d 1 913/918 not applicable 0.34(−0.28,0.96) z = 1.08,pz = 0.28
30-299 mg/d 4 311/312 0.52 0 1.03(−0.16,2.21) z = 1.70,pz = 0.09
≥ 300 mg/d 1 28/27 0.56 0 0.73(−6.15,7.61) z = 0.21,pz = 0.83
5. Whether combined with ACER or ARB
with ACEI or ARB 4 1218/1220 0.74 0 0.04(−0.04,0.12) z = 0.89,pz = 0.37
without ACEI or ARB 2 18/20 0.94 0 1.14(0.44,1.84) z = 3.20,pz = 0.001
6. Adjustment by treatment duration
< 1 year 3 72/71 0.47 0 0.69(−1.85,3.24) z = 0.53,pz = 0.59
1 ~ 3 years 3 1180/1186 0.56 0 0.48(−0.08,1.04) z = 1.68,pz = 0.09
7. Adjustment by dose of statins
low-intensity statins 3 1206/1211 0.81 0 0.42(−0.13,0.98) z = 1.51,pz = 0.13
moderate-intensity statins 2 20/19 0.27 19 3.07(−6.28,12.43) z = 0.64,pz = 0.52
high-intensity statins 1 26/27 0.80 0 2.76(−0.83,6.36) z = 1.51,pz = 0.13
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Table 3 Meta-analysis of the effect of statins on renal outcomes in diabetes (Continued)
8. Adjustment by baseline of eGFR
60 ~ 89 ml/min/1.73 m2 4 1234/1238 0.94 0 0.43(−0.12,0.98) z = 1.52,pz = 0.13
> =90 ml/min/1.73 m2 2 18/19 0.48 0 3.45(−0.40,7.30) z = 1.76,pz = 0.08
UAER
1. Overall 5 99/100 <0.00001 93 −1.68(−3.23,–0.12) z = 2.12,pz = 0.03
2. Adjustment by ethnicity
Caucasian 2 18/20 <0.00001 96 −25.99(−78.54,26.57) z = 0.97,pz = 0.33
Asian 3 81/80 0.0001 89 −1.78(−2.98,–0.57) z = 2.88,pz = 0.004
3. Adjustment by baseline of albuminuria
30-299 mg/d 4 67/69 <0.00001 94 −2.17(−4.56,0.23) z = 1.77,pz = 0.08
≥ 300 mg/d 1 32/31 not applicable −1.12(−1.65, −0.58) z = 4.11,pz < 0.0001
4. Adjustment by treatment duration
< 1 year 4 89/90 <0.00001 95 −1.90(−3.91,0.11) z = 1.85,pz = 0.06
1 ~ 3 years 1 10/10 not applicable −1.29(−2.28,–0.31) z = 2.58,pz = 0.010
5. Adjustment by dose of statins
low-intensity statins 1 10/10 not applicable −1.29(−2.28,–0.31) z = 2.58,pz = 0.010
moderate-intensity statins 1 8/10 not applicable −53.77(−73.67,–33.88) z = 5.30,pz < 0.00001
high-intensity statins 3 81/80 <0.00001 93 −1.39(−2.87,0.09) z = 1.84,pz = 0.07
Scr
1. Overall 4 127/126 <0.00001 95 0.75(−0.52,2.03) z = 1.15,pz = 0.25
2. Adjustment by baseline of albuminuria
30-299 mg/d 2 69/69 <0.00001 98 1.62(−1.91,5.15) z = 0.90,pz = 0.37
≥ 300 mg/d 2 58/57 0.93 0 −0.05(−0.42,0.31) z = 0.28,pz = 0.78
4. Adjustment by dose of statins
low-intensity statins 1 30/30 not applicable 3.44(2.62,4.25) z = 0.00,pz = 1.00
high-intensity statins 3 97/96 0.93 0 −0.10(−0.38,0.19) z = 0.98,pz = 0.33
BUN
1.Overall 2 51/52 0.88 0 −0.26(−0.64,0.13) z = 1.29,pz = 0.20
Abbreviations: N number of involved studies, Ph P values for heterogeneity of Q test, pz <0.05 indicate significant association, eGFR estimated Glomerular Filtration
Rate, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus, ACEI angiotensin-converting enzyme inhibitors, ARB Angiotensin II -receptor blockers, UAER
urinary albumin excretion rates, Scr serum creatinine, BUN blood urea nitrogen
Fig. 5 Forest plots of UAER (ug/min) for statins versus placebo in patients with diabetic nephropathy
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than 1 year. It indicated that the beneficial effect of
statins on albuminuria may depend on the duration of
statin treatment. Additionally, our study found that
statins can reduce albuminuria significantly in patients
of T2DM with diabetic nephropathy. Diseaes progres-
sion, duration of statin therapy and improved renal
blood flow are possible relevant factors [35, 36].
Some authors found statins may slow the decline in
eGFR [37, 38]. Nikolic et al. [32] suggested an overall
significant increase of GFR after statin therapy (increase
by 0.29 ml/min/1.73 m2, p = 0.04), with the greatest GFR
improvement after between 1 and 3 years of statin
therapy (0.50 ml/min/1.73 m2; p < 0.0001). However, our
meta-analysis found that statins did not improve eGFR
significantly. Just as Satirapoj said [30], as a post hoc
analysis, using estimates of renal function, some limita-
tions were observed in interpreting these data, so a small
proportion of patients, who had DN, were included in
this analysis, whereas our findings in the statin group re-
vealed eGFR did not improve, but no significant decline
was observed among DN subjects. Therefore, the avail-
able data on statin with eGFR in DN patients are still
conflicting, because of possible outcome reporting bias.
Findings from our meta-analysis revealed that statins
could reduce both albuminuria and the rate of progres-
sion of diabetic nephropathy. The benefits appear to
supplement those derived from treatment with renin-
angiotensin system (RAS) inhibitors [10]. The pathogen-
esis of diabetic nephropathy is multifactorial and its
precise mechanisms of action remain unclear. However, it
is now widely accepted that the rate of functional deteri-
oration correlates with the degree of the renal tubuloin-
terstitial fibrosis [36]. Statins is effective in protecting
against tubulointerstitial injury [10] and may slow down
the progression of diabetic nephropathy, but this needs to
be further validated in large-scale and long follow-up
period randomized controlled trials.
As with any study, our meta-analysis had some limita-
tions. Frist, the number of randomized controlled trials
was small and only published data included. Second, the
detection technique of albuminuria was different. Third,
the results are heavily based on the findings of the
CARDS trial, which represents more than 90 % of the
population of the meta-analysis. So, more clinical
researches with larger sample, higher quality and strictly
RCT study should be taken in the future.
Fig. 6 Funnel plot of publication bias for the effects of statins on renal outcomes in diabetic nephropathy
Fig. 7 Sensitivity analysis for the efficacy of statins on UAER in patients with diabetic nephropathy
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Conclusion
Statins reduce albuminuria and UAER significantly . The
beneficial effect of statins on renal function is time
dependent and better in type 2 diabeties patients with
nephropathy. Our findings, though exciting, still require
larger and high-quality studies to confirm the kidney
benefit of statins in patients with diabetes.
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